Why Are Ozone Catalysts Suitable for Pharmaceutical Wastewater Pretreatment?

Due to its high concentrations of refractory organic compounds and residual antibiotics, pharmaceutical wastewater exhibits low efficiency and system collapse risk under direct biochemical treatment. Catalytic ozonation technology can efficiently generate hydroxyl radicals at ambient temperatures and near‑neutral pH; it degrades pollutants non‑selectively and significantly improves wastewater biodegradability. This technology has already achieved successful engineering applications across numerous pharmaceutical production bases within China. This article analyzes the mechanistic basis for this technology’s suitability as well as its comprehensive advantages.

Ozone decomposition catalyst

jag. Sources and Treatment Challenges of Pharmaceutical Wastewater

Pharmaceutical wastewater mainly originates from active pharmaceutical ingredient (API) production, including fermentation filtrates, extraction residues, distillation bottoms, and equipment cleaning water. Water quality varies significantly across different wastewater types: antibiotic production wastewater typically has a Chemical Oxygen Demand (COD) of 5,000–20,000 mg/L and suspended solids of 5,000–23,000 mg/L; chemical synthesis pharmaceutical wastewater contains toxic substances like nitro compounds, anilines, and heavy metals; traditional Chinese medicine (TCM) production wastewater carries large amounts of refractory natural organic compounds, such as tannins, lignins, and alkaloids.

Even at concentrations as low as micrograms per liter, residual antibiotics can inhibit microbial metabolism and cause biochemical treatment systems to collapse. Moreover, chlorinated organics and polycyclic aromatic hydrocarbons (PAHs) have “three‑carcinogenic” effects (carcinogenic, mutagenic, teratogenic) and persist in water bodies. Therefore, we must apply effective pretreatment before biochemical processing to eliminate biological toxicity and enhance biodegradability.

II. The Core Mechanism of Ozone Catalysts

Ozone catalysts use transition metal oxides (e.g., manganese, copper, iron) as active components and support them on high‑surface‑area carriers like alumina or ceramics. As the ozone stream flows through the catalyst bed, active sites on the catalyst surface adsorb and activate ozone molecules, facilitating their cleavage to produce hydroxyl radicals (·OH).

With an oxidation potential as high as 2.80 V, hydroxyl radicals react non‑selectively and rapidly with most organic pollutants. They cleave saturated bonds and open aromatic rings, breaking large organic molecules into smaller intermediates, which then undergo further mineralization. The catalyst does not consume itself during the process; it operates efficiently at neutral pH (5–8), needs no chemical additives, and prevents secondary pollution.

III. Why It Is Particularly Suitable for Pharmaceutical Wastewater Pretreatment

1. Rapid Elimination of Antibiotic Bacteriostatic Activity

Hydroxyl radicals quickly attack the active functional groups of antibiotics (e.g., β‑lactam ring and tetracycline skeleton), causing ring‑opening and bond cleavage, thereby completely eliminating their bacteriostatic capability. Studies show that when we use a manganese‑based catalyst to treat oxytetracycline‑containing simulated wastewater, the antibiotic removal rate exceeds 96% within 30 minutes; furthermore, the resulting degradation products no longer inhibit subsequent biochemical treatment.

2. Efficient Degradation of Recalcitrant Organic Pollutants

Aromatic and heterocyclic compounds often resist conventional ozonation, with ozone utilization rates typically below 50%. The catalyst shifts the reaction toward a radical‑dominated, non‑selective oxidation process, accelerating degradation rates by several‑fold to tens‑fold. For instance, when we apply catalytic oxidation to a chemically synthesized pharmaceutical wastewater (COD ≈ 8,000 mg/L), the COD removal rate reaches 45%–55%, whereas conventional ozonation alone achieves less than 20%.

3. Significant Improvement in Biodegradability

Large, recalcitrant organic molecules break down into smaller substances—organic acids, aldehydes, and alcohols—raising the B/C ratio (BOD/COD) from an initial 0.1–0.2 to 0.3–0.5 or higher, sometimes up to 0.6. Consequently, subsequent biochemical treatment requires 30%–50% less hydraulic retention time and consumes 20%–30% less aeration energy.

4. Adaptability to Fluctuations in Water Quality and Flow Rate

By adjusting the ozone dosage (30–120 mg/L) and retention time (30–120 minutes), the system can flexibly adapt to varying pollutant loads; additionally, the fixed‑bed catalyst layer provides substantial buffering capacity.

IV. Advantages Over Traditional Pretreatment Technologies

Compared to the Fenton oxidation method—a common technique in pharmaceutical wastewater pretreatment—catalytic ozonation shows distinct advantages in multiple aspects. Regarding secondary pollution, Fenton oxidation requires adding ferrous sulfate and hydrogen peroxide under strongly acidic conditions. The reaction produces large amounts of iron‑containing sludge—about 1 till 3 kg per ton of wastewater—which we classify as hazardous waste and must dispose of at high cost. In contrast, catalytic ozonation needs no chemical additives; its solid catalyst is reusable, and the only by‑product is oxygen. Since the entire process generates no chemical sludge, it fundamentally avoids secondary pollution.

In terms of reaction conditions, Fenton oxidation requires us to adjust the wastewater pH to a strongly acidic range (2–4) and then add base after the reaction to restore neutrality. This consumes large quantities of acids and bases and complicates operation. Catalytic ozonation, however, can operate directly at ambient temperature and near‑neutral pH (5–8) of raw wastewater, without acid or base adjustments. This approach saves chemical costs and simplifies the overall workflow.

Regarding operational management, Fenton oxidation requires manual, periodic preparation and dosing of various reagents—a complex procedure with inherent safety risks. Conversely, catalytic ozonation systems can be highly automated; we can integrate them with a PLC for real‑time online water quality monitoring and automatic ozone output adjustment. The entire process runs autonomously, reducing the need for on‑site personnel and facilitating convenient management.

Regarding operating costs—taking a 500‑ton‑per‑day pharmaceutical wastewater treatment facility as an example—the Fenton process generates about 180 tons of iron‑containing hazardous waste annually. Hazardous waste disposal fees alone exceed 150,000 RMB; combined with acid, base, and other reagent costs, the direct operating cost per ton of wastewater amounts to approximately 4.5 RMB. For catalytic ozonation, electricity consumption (mainly for the ozone generator) costs about 2.8 RMB per ton, while the annual amortized catalyst depletion cost is roughly 0.4 RMB per ton. With no reagent or hazardous waste disposal costs, the total operating cost per ton is about 3.2 RMB—nearly 30% lower than the Fenton process. Dessutom, high‑quality ozone catalysts can remain effective for over two years under reasonable operating conditions; if their activity declines, we can restore much of their original efficacy through offline thermal regeneration, further extending service life and reducing replacement costs.

In summary, catalytic ozonation significantly outperforms the traditional Fenton oxidation process in environmental benefits, economic efficiency, and operational convenience.

V. Engineering Practice and Summary

Extensive engineering practice demonstrates that catalytic ozonation, when we apply it to pharmaceutical wastewater pretreatment, can achieve a COD removal rate of 40% till 60%. Dessutom, this process requires no pH adjustment and generates no chemical sludge, allowing prolonged stable system operation. The fundamental rationale for selecting catalytic ozonation for pharmaceutical wastewater pretreatment lies in its ability to simultaneously achieve three key objectives: reducing COD, eliminating antibiotic antibacterial activity, and significantly enhancing biodegradability—all without secondary pollution and with controllable operating costs. For pharmaceutical enterprises facing regulatory mandates to upgrade their environmental protection standards, catalytic ozonation represents a technically and economically sound pretreatment pathway that real‑world engineering applications have thoroughly validated.

author: Gloria
date:2026/5/13